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Abstract Cardiac L-type Ca2+ channel is facilitated by protein
kinase A (PKA)-mediated phosphorylation. Here, we investi-
gated the role of Ser1901, a putative phosphorylation site in the
carboxy-terminal of rat brain type-II K1C subunit (rbCII), in the
PKA-mediated regulation. Forskolin (3 WM) enhanced Ca2+
channel currents (ICa) and shifted the activation curve to negative
voltages, which were abolished by protein kinase inhibitor.
Replacement of Ser1901 of rbCII by Ala abolished the enhance-
ment of ICa by forskolin but not the shift of the activation curve.
These results indicate that Ser1901 is required for the PKA-
mediated enhancement of ICa, and that the voltage-dependence of
the activation of ICa appears to be modulated via another PKA
phosphorylation site. ß 2001 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
PKA-mediated phosphorylation is the crucial step in the
positive regulation of cardiac L-type Ca2 channels through
L-adrenergic receptor pathway [1]. Cardiac L-type Ca2 chan-
nel is composed of at least three subunits, pore-forming K1C
subunit, L subunit, and K2/N subunit. Target amino acids in
K1C and L subunits for PKA phosphorylation have been iden-
ti¢ed [2^6]. Ser1928 in the carboxy-terminal of rabbit cardiac
K1C subunit appears to be the only substrate within K1C sub-
unit for the PKA phosphorylation [3,7,8] and this Ser is highly
conserved among various species including human (see Fig.
1). However, the functional link between the PKA-mediated
modulation of Ca2 channel function and the PKA-mediated
phosphorylation of Ser1928 has been controversial [8,9]. Be-
cause of the di⁄culty in reconstituting the PKA-mediated
facilitation of L-type Ca2 channels in the expression system,
there are few successful reports dealing with the functional
role of phosphorylation sites [7^9]. The carboxy-terminal do-
main of K1C subunit has been shown to be involved in the
regulation of gating properties of the Ca2 channel [10]. Thus,
in the present study, aiming at clarifying the role of the phos-
phorylation site in the PKA-mediated modulation of L-type
Ca2 channels, we mutated Ser1901 of rat brain K1C subunit
(rbCII) that corresponds to Ser1928 in rabbit cardiac K1C sub-
unit. The approximate locations of putative phosphorylation
sites and Ser1901 are illustrated in Fig. 1A.
2. Materials and methods
2.1. Point mutation in rbCII
A point mutation was introduced into rbCII (kindly supplied by
Dr. T.P. Snutch) by replacing Ser1901 with Ala (S1901A). The muta-
tion was introduced into the XbaI (5933)^SacI (6391) fragment of
rbCII by use of a QuickChange Kit (Qiagen). The fragment was
ampli¢ed by polymerase chain reaction using Pfu polymerase (Stra-
tagene) and veri¢ed by sequence analysis. The K1C constructs were
subcloned into pcDNAIII vector.
2.2. Cell culture and transfection
BHK6 cells (baby hamster kidney cells) stably expressing rabbit
skeletal muscle L1a and K2/N subunits [11] were cultured as has been
described [12]. Wild-type K1C subunit (rbCII) or the mutated S1901A
were transiently expressed in BHK6 cells using SuperFect transfection
reagent (Qiagen). The transfected cells were identi¢ed by a green £uo-
rescent protein (GFP) signal coexpressed with K1C subunit (pEGFP-
C2, Invitrogen). Ca2 channel currents were detected in 60^80% of the
GFP-positive cells.
2.3. Electrophysiological recordings
L-type Ca2 channel currents (ICa) were measured in the whole-cell
con¢guration of patch-clamp technique as has been described [12].
The external solution contained (in mM): NaCl, 137; KCl, 5.4;
MgCl2, 1; HEPES, 10; glucose, 10 (pH adjusted to 7.4 with
NaOH). The resistance of the recording pipettes was between 1 and
4 M6 when ¢lled with the internal solution containing (in mM):
CsCl, 120; TEACl, 20; EGTA, 14; Mg-ATP, 5; Na2 creatine phos-
phate, 5; GTP, 0.2; HEPES, 10 (pH 7.3 adjusted with CsOH). In
some experiments, protein kinase inhibitor (PKI) was included in
the patch pipette at a ¢nal concentration of 20 WM.
ICa was measured using a patch/whole cell clamp ampli¢er (Nihon
Koden, Tokyo, Japan) or Axopatch 1D (Axon Instruments, Foster
City, CA, USA) via an A/D converter (Digidata 1200, Axon Instru-
ments, Foster City, CA, USA). Voltage-clamp protocols and data
acquisition were performed using pCLAMP6 software (Axon Instru-
ments, Foster City, CA, USA). Current signals were sampled at 2.5
kHz, ¢ltered at 5 kHz, then digitized and stored. Capacitative currents
were electrically compensated, and leak current was subtracted by P/-4
protocol. The ICa density ranged between 6 and 86 pA/pF. All the
experiments were performed at room temperature.
The half activation potential (V50) for the current^voltage relation-
ships (I^V curves) were determined by an interactive non-linear re-
gression ¢tting procedure to:
I  Vm3V revGmax1=f1 expVm3V50=kg 1
where Vm is the membrane potential, V50 is the half activation poten-
tial, Vrev is the reversal potential, k is the slope factor and Gmax is the
maximum of conductance.
Results are expressed as the mean þ S.E.M. Statistical analysis was
performed with Student’s paired t-test or when appropriate with Stu-
dent^Welch’s unpaired t-test.
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2.4. Drugs
Forskolin (Wako, Osaka, Japan) was dissolved in dimethyl sulfox-
ide (DMSO) and stored at 4‡C as a stock solution (3 mM). The ¢nal
concentration of DMSO in the bath solution was below 0.1% which,
we con¢rmed, had no direct e¡ect on ICa (data not shown). PKI
(Sigma, St. Louis, MO, USA) was dissolved in double distilled water
at 0.4 mM with 0.1 mg/ml of bovine albumin (essentially fatty acid
free) (Sigma, St. Louis, MO, USA) as a stock solution and stored at
320‡C.
3. Results
Fig. 2B shows typical Ca2 channel currents (ICa) recorded
with 2 mM Ca2 as a charge carrier. The individual I^V curve
exhibited typical properties as ICa. Because of the large var-
iation of ICa density (from 6 to 67 pA/pF at 0 mV test poten-
tial), I^V curves were normalized to the maximum value of
peak currents, typically measured at 310 or 0 mV, and shown
in Fig. 2D. Forskolin at 3 WM augmented ICa, as is observed
in native cardiac myocytes, within 7 min after switching the
external solution [1] (Fig. 2A). The relative increment of ICa
by forskolin varied widely from cell to cell (1.00^2.50-fold,
average 1.53 þ 0.15-fold, n = 12, Fig. 4). However, the appli-
cation of forskolin at higher concentration, such as 10 WM,
rather inhibited ICa, which could be due to the direct e¡ects of
forskolin on Ca2 channels [13,14] (data not shown, n = 3).
Forskolin induced dual e¡ects similar to those observed in
native cardiac myocytes upon L-adrenergic receptor stimula-
tion [1]: the enhancement of the peak amplitude of ICa at all
test potentials and the hyperpolarizing shift of the I^V curve
(Figs. 2B^D and 5A).
To verify that the forskolin-induced e¡ects were mediated
by PKA, we applied 20 WM of PKI into cells through the
patch pipette. Current recordings were started at least 10
min after membrane rupture in order to give enough time
for the di¡usion of PKI into the cell. PKI by itself did not
a¡ect the amplitude of ICa, suggesting that the basal PKA
activity is not high enough to modify ICa. Therefore, ICa
and its I^V curve measured in the presence of PKI was indis-
tinguishable from those recorded in the absence of PKI (Fig.
2E,G). However, in the presence of PKI, the subsequent ap-
plication of forskolin showed neither the enhancement of the
peak ICa amplitude nor the shift of I^V relationships (Fig.
2G). Peak ICa amplitude gradually decreased during the ap-
plication of forskolin to 0.89 þ 0.03-fold of control (n = 5)
(Fig. 4), in a way similar to that of vehicle control measured
with 0.1% DMSO (0.85 þ 0.06, n = 3, data not shown). V50
values determined in control experiments were 310.6 þ 1.3
and 315.6 þ 1.2 mV before and after application of forskolin,
respectively (n = 11, P6 0.05, Fig. 5A). In contrast, in the
presence of PKI, V50 values were 313.5 þ 1.8 and
Fig. 1. Schematic drawing of the voltage-gated L-type Ca2 channel.
A: Putative phosphorylation sites, including Ser1901, are shown as
gray circle. B: Amino acid sequences around Ser1901 are highly con-
served in various species and organs. All of K1C variants contain
consensus sequences of PKA substrate such as RRAS (amino acids
1898^1901 in rbCII).
Fig. 2. The e¡ect of forskolin on ICa recorded in rbCII expressed in
BHK6 cells. A: Representative time course of enhancement of peak
ICa during application of forskolin to rbCII. ICa was elicited by
pulses to 0 mV from a holding potential of 370 mV every 15 s. In-
set shows current traces recorded at time points indicated by arrows
a and b. B: Current traces elicited by depolarization to 340, 320,
0 and +20 for 100 ms from a holding potential of 370 mV. C:
Current traces in the presence of forskolin (3 WM) recorded from
the same cell as shown in B. D: Current^voltage relationships (I^V
curves) measured in the absence (F) and the presence (E) of forsko-
lin (3 WM) are superimposed. The peak amplitude of ICa was nor-
malized to the maximum peak ICa of control recordings. E and F:
Current traces recorded under the same condition as used in B and
C, respectively, with the intracellular application of PKI (20 WM)
through the patch pipette. Traces in E and F were recorded from
the same cell. G: I^V curves measured after the intracellular appli-
cation of PKI are superimposed.
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313.1 þ 2.4 mV before and after application of forskolin, re-
spectively (n = 5, Fig. 5B). These results demonstrate that the
dual e¡ects of forskolin on Ca2 channel currents were medi-
ated by PKA-dependent phosphorylation.
The mutant K1C subunit (S1901A) produced Ca2 channel
currents with the current density ranging between 13 and 86
pA/pF at 0 mV test potential, which was not statistically
di¡erent from that of rbCII. We con¢rmed that the molecular
size of the mutated K1C subunit expressed in BHK6 cells is
identical to that of rbCII (V220 kDa) by Western blotting
(data not shown). Neither gating kinetics nor I^V curves dif-
fered from those recorded in the wild-type K1C (rbCII) (Fig.
3B,D), indicating that the point mutation did not cause gross
misfolding of K1C subunit protein or the change of gating
properties. In S1901A, however, forskolin (3 WM) failed to
enhance ICa even after more than 7 min of application (Fig.
3A). The peak ICa amplitude gradually decreased to
0.93 þ 0.04-fold of initial amplitude (n = 10) during the appli-
cation of forskolin, which was almost identical to the results
obtained in the presence of PKI, 0.93 þ 0.05-fold of control
(n = 5, Fig. 4). These results indicate that the PKA-mediated
enhancement of ICa requires Ser1901 of rbCII.
Interestingly, in S1901A, forskolin continued to produce the
hyperpolarizing shift of the activation curve (Figs. 3D and
5C). V50 values determined in S1901A were 312.6 þ 1.1 and
316.3 þ 1.2 mV, before and after application of forskolin,
respectively (n = 9, P6 0.05). This e¡ect of forskolin was
mostly absent in the presence of PKI (Figs. 3G and 5D).
V50 values were 312.4 þ 0.9 and 314.1 þ 2.0 mV, before and
after application of forskolin, respectively (n = 5, not signi¢-
cant). These results indicate that the forskolin-induced hyper-
polarizing shift of the I^V curve is indeed due to the PKA-
Fig. 3. The e¡ect of forskolin on ICa recorded from S1901A ex-
pressed in BHK6 cells. A: A representative time course of peak ICa
during the application of forskolin to S1901A. The procedures were
the same as those of Fig. 2A. Inset shows the current traces re-
corded at time points indicated by arrows a and b. B and C: Cur-
rent traces recorded from S1901A in the absence (B) and the pres-
ence (C) of forskolin (3 WM). D: I^V curves are shown after the
peak amplitude of ICa was normalized to the maximum ICa of con-
trol recording. E and F: Current traces recorded from the same cell
in the absence and the presence of forskolin after the intracellular
dialysis of PKI (20 WM) through the patch pipette. G: I^V curves
measured in the presence of PKI (20 WM) are superimposed.
Fig. 4. Enhancement of ICa amplitude by forskolin was abolished in
S1901A. Relative amplitudes of peak ICa in the presence of forsko-
lin (3 WM) are summarized. Each symbol (U) represents the individ-
ual relative ICa amplitude measured in the presence of forskolin.
The voltage protocols for recording ICa were as shown in Fig. 2. A:
On top of each column, the mean value and the number of experi-
ments are indicated. *, P6 0.05.
Fig. 5. The e¡ect of forskolin on activation potentials of ICa mea-
sured in rbCII and S1901A. To compare the e¡ect of forskolin on
activation potential, I^V curves measured in the absence (F) and
the presence (E) of forskolin (3 WM) were normalized to the respec-
tive maximum peak ICa amplitude and superimposed so that the
negative shift of the activation curves can be compared. The data as
shown in Figs. 2D,G and 3D,G were re-drawn.
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dependent phosphorylation of a target protein that is distinct
from Ser1901 of K1C subunit.
4. Discussion
In native cardiac myocyte, the stimulation of L-adrenergic
receptor causes the activation of PKA and then modulation of
L-type Ca2 channels characterized by the enhancement of ICa
density and the negative shift of I^V relationships [1]. In the
present study, we could reconstitute these e¡ects in BHK6
cells expressing the L-type Ca2 channel by the application
of forskolin. BHK cells may be equipped with the intracellular
environment and endogenous kinases required for the modu-
lation of L-type Ca2 channels as reported before [15]. Taking
advantage of this expression system, we showed that Ser1901
plays a critical role in the PKA-mediated enhancement of
Ca2 channel current, but not in the PKA-mediated negative
shift of the activation curve.
In the present study, we coexpressed K1C and K2/N subunits
together with L1a subunit that has been shown to associate
with K1C subunit and to modulate its function [16]. It has been
reported that cardiac myocytes express L2 subunits as an ac-
cessory subunit of L-type Ca2 channels [17,18]. However, for
instance, L2a subunit co-expressed with K1C and K2/N subunits
failed to reconstitute the Ca2 channel current that shows fast
inactivation kinetics in cardiac myocytes [19]. In human heart,
L1a, L1b and L1c subunits have been detected, while other
subtypes of L subunits are detected in other species [20].
Thus, the real L subunit associated with K1C subunit in heart
has not been identi¢ed.
In this study, we showed that Ser1901 plays a critical role in
the PKA-mediated enhancement of ICa. However, it has been
reported that the distal portion of carboxy-terminus of K1C
subunit may be cleaved o¡ by proteolytic processing in the
native cardiac myocytes [3], which suggests that Ser1901 may
not be involved in the PKA-mediated regulation [9]. However,
the cleaved carboxy-terminal portion may be associated with
the membrane near the Ca2 channel even after the proteo-
lytic cleavage [21], and that portion appears to be colocalized
with Ca2 channels in cardiac myocytes at t-tubular mem-
branes [18]. Thus, it is possible that Ser1901 continues to par-
ticipate in the PKA-dependent modulation of Ca2 channels
even after the proteolytic truncation.
What could be the molecular mechanism underlying the up-
regulation of Ca2 channel activity subsequent to the phos-
phorylation of Ser1901 ? L-adrenergic receptor stimulation in-
creases the open probability of L-type Ca2 channels without
changing the number of Ca2 channels [22]. The deletion of
K1C subunit carboxy-terminal resulted in the enhancement of
current density without signi¢cant e¡ect on gating charge
movement [10]. Therefore, the carboxy-terminal of K1C sub-
unit may serve as an inhibitory domain of Ca2 channel gat-
ing, which may be removed on the PKA-dependent phosphor-
ylation of Ser1901.
We showed that the negative shift of I^V relationships in-
duced by PKA did not result from the phosphorylation of
Ser1901. These results suggest that another PKA substrate is
responsible for the modulation of the voltage-dependence of
activation of L-type Ca2 channels. Single channel studies on
cardiac Ca2 channels have predicted the multiple phosphor-
ylation sites involved in the regulation of distinct properties of
the Ca2 channel [23,24]. In the present study, we showed that
the enhancement of ICa and the negative shift of current^volt-
age relationships appear to be independently regulated via
distinct phosphorylation sites. We predict that the possible
target could be L subunit based on several reasons: (1) it is
unlikely that there are substrates for PKA other than Ser1901
within Ca2 channel K1C subunits [3], (2) Ca2 channel L1a
subunit used in this study is a substrate of PKA phosphory-
lation [2], (3) L subunit modulates the current^voltage rela-
tionships when co-expressed with K1C [16]. It is also possible
that the PKA phosphorylation of other proteins associated
with Ca2 channels mediate the negative shift of I^V relation-
ships.
In summary, we have shown that Ser1901 in the carboxy-
terminal of K1C subunit of Ca2 channel is required for the
PKA-mediated enhancement of ICa, and that I^V curves of
S1901A as well as rbCII were shifted to hyperpolarized po-
tentials by PKA stimulation.
We conclude that PKA-mediated modulation of L-type
Ca2 channel involves at least two independent mechanisms,
enhancement of ICa density via phosphorylation of Ser1901,
and negative shift of activation curve via phosphorylation of
another site that is to be elucidated in future studies.
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